Literature DB >> 1458711

Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE.

W Bencivelli1, C Vitali, D A Isenberg, J S Smolen, M L Snaith, M Sciuto, S Bombardieri.   

Abstract

In the first phase of this study, a data-base containing clinical and laboratory findings of 704 patients with systemic lupus erythematosus (SLE), originating from 29 centres and 14 countries, was used to assess the validity of 4 common indices of disease activity, SLAM, BILAG, SLEDAI and SIS. The physician's judgement of activity was assumed as the unique reference criterion (gold standard). Computer programmes were developed to calculate automatically the 4 activity indices; this computation appeared to correspond with manual computations in a sample of 60 appropriately selected cases. All 4 indices were closely correlated with each other (r in the range of 0.716 to 0.872), and with the physician's score (r in the range of 0.620 to 0.719). In the second phase of the study the activity index developed in part I (ECLAM) was prospectively validated, and its performance compared to that of the other scales, both as a single state index and as a transition index (i.e., its ability to assess disease activity at a single point in time and to detect variations in consecutive readings). A computer-assisted clinical chart was prepared for this purpose. This chart allowed us to calculate automatically all the indices. Two consecutive observation times (time 0, and time 1 three months later) were included in the study protocol. Data on 75 patients from 19 centres were collected, and each patient was observed twice. All the computed indices were closely correlated, both at time 0 (r ranging from 0.725 to 0.884), and at time 1 (r ranging from 0.607 to 0.833).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1458711

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  24 in total

1.  Toward the development of criteria for global flares in juvenile systemic lupus erythematosus.

Authors:  Hermine I Brunner; Marisa S Klein-Gitelman; Gloria C Higgins; Sivia K Lapidus; Deborah M Levy; Anne Eberhard; Nora Singer; Judyann C Olson; Karen Onel; Marilynn Punaro; Laura Schanberg; Emily von Scheven; Jun Ying; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

2.  Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Gloria C Higgins; Marisa S Klein-Gitelman; Sivia K Lapidus; Judyann C Olson; Karen Onel; Marilynn Punaro; Jun Ying; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

Review 3.  [Systemic lupus erythematosus--activity and outcome].

Authors:  M Aringer; J Smolen
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

4.  Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Gloria C Higgins; Kristina Wiers; Sivia K Lapidus; Judyann C Olson; Karen Onel; Marilynn Punaro; Jun Ying; Marisa S Klein-Gitelman; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-03       Impact factor: 4.794

5.  Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study.

Authors:  Alimohammad Fatemi; Ahmad Raeisi; Zahra Sayedbonakdar; Abbas Smiley
Journal:  Clin Rheumatol       Date:  2017-12-18       Impact factor: 2.980

6.  Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus.

Authors:  K Manger; B Manger; R Repp; M Geisselbrecht; A Geiger; A Pfahlberg; T Harrer; J R Kalden
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 7.  How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets.

Authors:  Virginia Pascual; Florence Allantaz; Pinakeen Patel; A Karolina Palucka; Damien Chaussabel; Jacques Banchereau
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

8.  Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy.

Authors:  A Doria; A Ghirardello; M Boscaro; M L Viero; E Vaccaro; G M Patrassi; P F Gambari
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

9.  A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus.

Authors:  Damien Chaussabel; Charles Quinn; Jing Shen; Pinakeen Patel; Casey Glaser; Nicole Baldwin; Dorothee Stichweh; Derek Blankenship; Lei Li; Indira Munagala; Lynda Bennett; Florence Allantaz; Asuncion Mejias; Monica Ardura; Ellen Kaizer; Laurence Monnet; Windy Allman; Henry Randall; Diane Johnson; Aimee Lanier; Marilynn Punaro; Knut M Wittkowski; Perrin White; Joseph Fay; Goran Klintmalm; Octavio Ramilo; A Karolina Palucka; Jacques Banchereau; Virginia Pascual
Journal:  Immunity       Date:  2008-07-18       Impact factor: 31.745

10.  [Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus].

Authors:  G Chehab; O Sander; R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2007-07       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.